Nasus Pharma Ltd. (AMEX:NSRX) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares and accompanying warrants Closed: US$15M raised · US$5.565 a share · 1 warrant at US$6.53 for 24 months · Citizens Capital Markets +1 Dealers: Citizens Capital Markets (lead), Laidlaw & Company (UK) Ltd. Insiders: Certain members of the Company's Board of Directors are participating Use of proceeds: Advance pivotal clinical development of NS002 for anaphylaxis, start first-in-human studies for other pipeline products, working capital and general purposes | Feb 13, 2026 |
| Public offering of ordinary shares Closed: US$10M raised · US$8 a share · Laidlaw & Company (UK) Ltd. +1 Dealers: Laidlaw & Company (UK) Ltd. (co-lead), Craft Capital Management LLC (co-lead) Use of proceeds: Development of intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies; general corporate purposes and working capital | Aug 14, 2025 |